Epstein leaving Novartis amid pharma reorganization

Novartis AG (NYSE:NVS; SIX:NOVN) said it will split its pharmaceuticals division into two new units, Novartis Pharmaceuticals and Novartis Oncology, which together will form Novartis' new Innovative Medicines division. The company said David Epstein, division head and CEO of the existing Novartis Pharmaceuticals, will leave the company.

The new Novartis Pharmaceuticals unit will house the company's neurology, ophthalmology, immunology, dermatology, respiratory, cardiometabolic and established medicines programs. Novartis Oncology will include cancer programs as well as cell and gene therapies. ...